Discovery of INCB3284, a potent, selective, and orally bioavailable hCCR2 antagonist

ACS Medicinal Chemistry Letters

Volumn 2, Issue 6, 2011, Pages 450-454

  Xue, Chu Biao ^a   Feng, Hao ^a   Cao, Ganfeng ^a   Huang, Taisheng ^a   Glenn, Joseph ^a   Anand, Rajan ^a   Meloni, David ^a   Zhang, Ke ^a   Kong, Lingquan ^a   Wang, Anlai ^a   Zhang, Yingxin ^a   Zheng, Changsheng ^a   Xia, Michael ^a   Chen, Lihua ^a   Tanaka, Hiroyuki ^a   Han, Qi ^a   Robinson, D J ^a   Modi, Dilip ^a   Storace, Lou ^a   Shao, Lixin ^a   Sharief, Vaqar ^a   Li, Mei ^a   Galya, Laurine G ^a   Covington, Maryanne ^a   Scherle, Peggy ^a   Diamond, Sharon ^a   Emm, Tom ^a   Yeleswaram, Swamy ^a   Contel, Nancy ^a   Vaddi, Kris ^a   Newton, Robert ^a   Hollis, Greg ^a   Friedman, Steven ^a   Metcalf, Brian ^a   more..

^a Clinical Development   (United States)

Author keywords

antagonist; CCR2; chemokine; hERG; oral absorption

Indexed keywords

CHEMOKINE RECEPTOR CCR2; INCB 3284; MONOCYTE CHEMOTACTIC PROTEIN 1; POTASSIUM CHANNEL HERG;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; IC 50; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POTASSIUM CURRENT; PRIORITY JOURNAL;

PRIMATES; RODENTIA;

EID: 79959248212     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200030q     Document Type: Article

References (12)

1. Kinne, R. W.; Brauer, R.; Stuhlmuller, B.; Palombo-Kinne, E.; Burmester, G. Macrophages in rheumatoid arthritis Arthritis Res. 2000, 2, 189-202 (Pubitemid 32223726)
2. Power, C. A.; Proudfoot, A. E. The chemokine system: Novel broad-spectrum therapeutic targets Curr. Opin. Pharmacol. 2001, 1, 417-424 (Pubitemid 33585993)
3. Feria, M.; Diaz-Conzalez, F. The CCR2 receptor as a therapeutic target Expert Opin. Ther. Pat. 2006, 16, 49-57 (Pubitemid 43056402)
4. Xia, M.; Sui, Z. Recent development in CCR2 antagonists Expert Opin. Ther. Pat. 2009, 19, 295-303
5. Pease, J. E.; Horuk, R. Chemokine receptor antagonists: Part I Expert Opin. Ther. Pat. 2009, 19, 39-58
6. Struthers, M.; Pasternak, A. CCR2 antagonists Curr. Top. Med. Chem. 2010, 10, 1278-1298
7. Pasternak, A.; Goble, S. D.; Struthers, M.; Vicario, P. P.; Ayala, J. M.; Di Salvo, J.; Kilburn, R.; Wisniewski, T.; DeMartino, J. A.; Mills, S. G.; Yang, L. Discovery of a potent and orally bioavailable CCR2 and CCR5 dual antagonist ACS Med. Chem. Lett. 2010, 1, 14-18
8. Cherney, R. J.; Mo, R.; Meyer, D. T.; Voss, M. E.; Yang, M. G.; Santella, J. B., III; Duncia, J. V.; Lo, Y. C.; Yang, G.; Miller, P. B.; Scherle, P. A.; Zhao, Q.; Mandlekar, S.; Cvijic, M. E.; Barrish, J. C.; Decicco, C. P.; Carter, P. H. γ-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists Bioorg. Med. Chem. Lett. 2010, 20, 2425-2430
9. Peace, S.; Philp, J.; Brooks, C.; Piercy, V.; Moores, K.; Smethurst, C.; Watson, S.; Gaines, S.; Zippoli, M.; Mookherjee, C.; Ife, R. Identification of a sulfonamide series of CCR2 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 3961-3964
10. Xue, C.-B.; Wang, A.; Meloni, D.; Zhang, K.; Kong, L.; Feng, H.; Glenn, J.; Huang, T.; Zhang, Y.; Cao, G.; Anand, R.; Zheng, C.; Xia, M.; Han, Q.; Robinson, D. J.; Storace, L.; Shao, L.; Li, M.; Brodmerkel, C. M.; Covington, M.; Scherle, P.; Diamond, S.; Yeleswaram, S; Vaddi, K.; Newton, R.; Hollis, G.; Friedman, S.; Metcalf, B. Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2 Bioorg. Med. Chem. Lett. 2010, 20, 7473-7478
11. Aronov, A. M. Predictive in silico modeling for hERG channel blockers Drug Discovery Today 2005, 10, 149-155 (Pubitemid 40247813)
12. Farid, R.; Day, T.; Friesner, R. A.; Pearlstein, R. A. New insight about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies Bioorg. Med. Chem. 2006, 14, 3160-3173